Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Immunogenicity and Safety of GSK Biologicals' Influenza Vaccine Versus a Licensed Comparator in Children

2. juli 2018 oppdatert av: GlaxoSmithKline

Immunogenicity and Safety of GSK Biologicals' Thimerosal-free TIV Flu Vaccine Versus a Licensed Comparator in Children

The purpose of this study is to evaluate the immunogenicity and the safety of GlaxoSmithKline Biologicals' seasonal influenza vaccine, Fluarix, compared to Fluzone (a US-licensed vaccine) in children, 6 to 35 months of age.

Studieoversikt

Status

Fullført

Forhold

Studietype

Intervensjonell

Registrering (Faktiske)

3317

Fase

  • Fase 3

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

    • Alabama
      • Birmingham, Alabama, Forente stater, 35244
        • GSK Investigational Site
      • Birmingham, Alabama, Forente stater, 35205
        • GSK Investigational Site
      • Dothan, Alabama, Forente stater, 36305
        • GSK Investigational Site
    • Arkansas
      • Benton, Arkansas, Forente stater, 72019
        • GSK Investigational Site
      • Conway, Arkansas, Forente stater, 72034
        • GSK Investigational Site
      • Fayetteville, Arkansas, Forente stater, 72703
        • GSK Investigational Site
      • Jonesboro, Arkansas, Forente stater, 72401
        • GSK Investigational Site
      • Little Rock, Arkansas, Forente stater, 72205
        • GSK Investigational Site
    • California
      • Huntington Beach, California, Forente stater, 92647
        • GSK Investigational Site
      • Long Beach, California, Forente stater, 90806
        • GSK Investigational Site
      • Paramount, California, Forente stater, 90723
        • GSK Investigational Site
      • Sacramento, California, Forente stater, 95816
        • GSK Investigational Site
      • San Francisco, California, Forente stater, 94102
        • GSK Investigational Site
      • West Covina, California, Forente stater, 91790
        • GSK Investigational Site
    • Colorado
      • Longmont, Colorado, Forente stater, 80501
        • GSK Investigational Site
    • Connecticut
      • Norwich, Connecticut, Forente stater, 06360
        • GSK Investigational Site
    • Idaho
      • Nampa, Idaho, Forente stater, 83686
        • GSK Investigational Site
    • Illinois
      • DeKalb, Illinois, Forente stater, 60115
        • GSK Investigational Site
    • Indiana
      • New Albany, Indiana, Forente stater, 47150
        • GSK Investigational Site
    • Kansas
      • Arkansas City, Kansas, Forente stater, 67005
        • GSK Investigational Site
      • Newton, Kansas, Forente stater, 67114
        • GSK Investigational Site
      • Wichita, Kansas, Forente stater, 67207
        • GSK Investigational Site
    • Kentucky
      • Bardstown, Kentucky, Forente stater, 40004
        • GSK Investigational Site
      • Louisville, Kentucky, Forente stater, 40207
        • GSK Investigational Site
    • Louisiana
      • Bossier City, Louisiana, Forente stater, 71111
        • GSK Investigational Site
      • Metairie, Louisiana, Forente stater, 70006
        • GSK Investigational Site
    • Michigan
      • Stevensville, Michigan, Forente stater, 49127
        • GSK Investigational Site
    • Minnesota
      • Saint Paul, Minnesota, Forente stater, 55108
        • GSK Investigational Site
    • Missouri
      • Saint Louis, Missouri, Forente stater, 63141
        • GSK Investigational Site
    • Nebraska
      • Omaha, Nebraska, Forente stater, 68134
        • GSK Investigational Site
    • Nevada
      • Henderson, Nevada, Forente stater, 89015
        • GSK Investigational Site
    • New York
      • Cortland, New York, Forente stater, 13045
        • GSK Investigational Site
    • North Carolina
      • Boone, North Carolina, Forente stater, 28607
        • GSK Investigational Site
      • Cary, North Carolina, Forente stater, 27518
        • GSK Investigational Site
      • Raleigh, North Carolina, Forente stater, 27609
        • GSK Investigational Site
    • North Dakota
      • Fargo, North Dakota, Forente stater, 58103
        • GSK Investigational Site
    • Ohio
      • Austintown, Ohio, Forente stater, 44515
        • GSK Investigational Site
      • Cincinnati, Ohio, Forente stater, 45245
        • GSK Investigational Site
      • Cleveland, Ohio, Forente stater, 44121
        • GSK Investigational Site
      • Dayton, Ohio, Forente stater, 45406
        • GSK Investigational Site
    • Oregon
      • Gresham, Oregon, Forente stater, 97030
        • GSK Investigational Site
    • Pennsylvania
      • Erie, Pennsylvania, Forente stater, 16505
        • GSK Investigational Site
      • Greenville, Pennsylvania, Forente stater, 16125
        • GSK Investigational Site
      • Latrobe, Pennsylvania, Forente stater, 15650
        • GSK Investigational Site
      • Pittsburgh, Pennsylvania, Forente stater, 15236
        • GSK Investigational Site
      • Uniontown, Pennsylvania, Forente stater, 15401
        • GSK Investigational Site
      • Wexford, Pennsylvania, Forente stater, 15090
        • GSK Investigational Site
    • South Carolina
      • Charleston, South Carolina, Forente stater, 29406
        • GSK Investigational Site
    • Tennessee
      • Clarksville, Tennessee, Forente stater, 37043
        • GSK Investigational Site
      • Jackson, Tennessee, Forente stater, 38305
        • GSK Investigational Site
      • Kingsport, Tennessee, Forente stater, 37660
        • GSK Investigational Site
    • Texas
      • Austin, Texas, Forente stater, 78705
        • GSK Investigational Site
      • Fort Worth, Texas, Forente stater, 76135
        • GSK Investigational Site
      • Houston, Texas, Forente stater, 77055
        • GSK Investigational Site
      • San Angelo, Texas, Forente stater, 76904
        • GSK Investigational Site
    • Utah
      • Bountiful, Utah, Forente stater, 84010
        • GSK Investigational Site
      • Layton, Utah, Forente stater, 84041
        • GSK Investigational Site
      • Murray, Utah, Forente stater, 84107
        • GSK Investigational Site
      • Provo, Utah, Forente stater, 84604
        • GSK Investigational Site
      • Roy, Utah, Forente stater, 84067
        • GSK Investigational Site
      • South Jordan, Utah, Forente stater, 84095
        • GSK Investigational Site
    • Virginia
      • Burke, Virginia, Forente stater, 22015
        • GSK Investigational Site
      • Pokfulam, Hong Kong
        • GSK Investigational Site
      • Shatin, Hong Kong
        • GSK Investigational Site
      • Mexico, Mexico, 6720
        • GSK Investigational Site
      • Mexico city, Mexico, 04530
        • GSK Investigational Site
      • Taipei, Taiwan, 104
        • GSK Investigational Site
      • Taipei, Taiwan
        • GSK Investigational Site
      • Bangkok, Thailand, 10400
        • GSK Investigational Site

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

6 måneder til 2 år (Barn)

Tar imot friske frivillige

Ja

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  • A male or female child aged 6 to 35 months at the time of the first vaccination; children who may or may not have had previous administration of influenza vaccine in a previous season are acceptable.
  • Subjects having a parent/guardian who the investigator believes can and will comply with the requirements of the protocol.
  • Written informed consent obtained from the subject's parent/guardian.

Exclusion Criteria:

  • Use of any investigational or non-registered product (drug or vaccine) within 30 days preceding the administration of the study vaccine, or planned use during the study period. Routine, registered childhood vaccinations are not an exclusion criterion.
  • History of hypersensitivity to any vaccine.
  • History of allergy or reactions likely to be exacerbated by any component of the vaccine.
  • Acute disease at the time of enrolment.
  • History of Guillain Barré syndrome within 6 weeks of receipt of prior inactivated influenza virus vaccine.
  • Receipt of an influenza vaccine outside of this study, during current (2008-09) flu season.
  • Administration of immunoglobulins and/or blood products within the 3 months preceding the first dose of study vaccine or planned administration during the study period.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Forebygging
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Dobbelt

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Fluarix Dose A Group

Subjects were administered 1 or 2 doses* of Fluarix vaccine (at Day 0 or at Days 0 and 28) intramuscularly, in the non-dominant upper arm (children >12 months of age) or in the anterolateral thigh (children <12 months of age).

* Only those subjects who had no history of prior influenza vaccination (i.e. unprimed subjects) received 2 doses.

One (Day 0) or two (Day 0 and Day 28) doses by intramuscular injection. Two different doses are tested.
Eksperimentell: Fluarix Dose B Group

Subjects were administered 1 or 2 doses*, half the volume of dose A, of Fluarix vaccine (at Day 0 or at Days 0 and 28) intramuscularly, in the non-dominant upper arm (children >12 months of age) or in the anterolateral thigh (children <12 months of age).

* Only those subjects who had no history of prior influenza vaccination (i.e. unprimed subjects) received 2 doses.

One (Day 0) or two (Day 0 and Day 28) doses by intramuscular injection. Two different doses are tested.
Aktiv komparator: Fluzone Group

Subjects were administered 1 or 2 doses* of Fluzone vaccine (at Day 0 or at Days 0 and 28) intramuscularly, in the non-dominant upper arm (children >12 months of age) or in the anterolateral thigh (children <12 months of age).

* Only those subjects who had no history of prior influenza vaccination (i.e. unprimed subjects) received 2 doses.

One (Day 0) or two (Day 0 and Day 28) doses by intramuscular injection.

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Geometric Mean Titer (GMT) of Serum Anti-hemagglutinin (HA) Antibodies Against Each of the Influenza Vaccine Strains
Tidsramme: Day 0 (PRE), Day 28 or Day 56 (POST)

GMTs and their 95% confidence interval are presented for all 3 viral strains comprised in the vaccine.

Post-vaccination timepoints: Day 28 for primed or Day 56 for unprimed subjects

Day 0 (PRE), Day 28 or Day 56 (POST)
Number of Subjects Who Seroconverted
Tidsramme: Day 28 or Day 56

Seroconversion is defined as the number of subjects with either a pre-vaccination anti-HA titer < 1:10 and a post-vaccination titer ≥ 1:40, or a pre-vaccination titer ≥ 1:10 and a minimum 4-fold increase at post-vaccination titer.

Post-vaccination timepoints: Day 28 for primed or Day 56 for unprimed subjects

Day 28 or Day 56

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Number of Seroprotected Subjects
Tidsramme: Day 0 (PRE), Day 28 or Day 56 (POST)

A seroprotected subject is a subject with a serum anti-HA titer

≥ 1:40

Post-vaccination timepoints: Day 28 for primed or Day 56 for unprimed subjects

Day 0 (PRE), Day 28 or Day 56 (POST)
Seroconversion Factor
Tidsramme: Day 28 or Day 56

Seroconversion factor is defined as the fold increase in serum anti-HA GMTs post-vaccination (Day 28 or 56) compared to pre-vaccination (Day 0).

Post-vaccination timepoints: Day 28 for primed or Day 56 for unprimed subjects

Day 28 or Day 56
Number of Subjects Reporting Solicited Local Symptoms
Tidsramme: During a 4-day follow-up period after vaccination
Solicited local symptoms assessed include pain, redness and swelling.
During a 4-day follow-up period after vaccination
Number of Subjects Reporting Solicited General Symptoms
Tidsramme: During a 4-day follow-up period after vaccination
Solicited general symptoms assessed include drowsiness, irritability, loss of appetitie, and temperature.
During a 4-day follow-up period after vaccination
Number of Subjects Reporting Unsolicited Adverse Events (AE)
Tidsramme: During a 28-day follow-up period after vaccination
An AE is any untoward medical occurrence in a clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product
During a 28-day follow-up period after vaccination
Number of Subjects Reporting Serious Adverse Events (SAE) and New Onset of Chronic Diseases (NOCD)
Tidsramme: During the entire study (Day 0 until Month 6)

An SAE is any untoward medical occurrence that: results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study subject, or may evolve into one of the outcomes listed above.

NOCDs assessed include for example: diabetes, asthma, allergies, autoimmune disease, cancer, neuropathic disorders

During the entire study (Day 0 until Month 6)
Number of Subjects Reporting Rare Serious Events
Tidsramme: During the entire study (Day 0 until Month 6)
Rare serious events have an occurrence rate of 1/300 (0.3%).
During the entire study (Day 0 until Month 6)

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Sponsor

Publikasjoner og nyttige lenker

Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart

1. oktober 2008

Primær fullføring (Faktiske)

5. mars 2009

Studiet fullført (Faktiske)

1. juni 2009

Datoer for studieregistrering

Først innsendt

1. oktober 2008

Først innsendt som oppfylte QC-kriteriene

1. oktober 2008

Først lagt ut (Anslag)

2. oktober 2008

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

31. juli 2018

Siste oppdatering sendt inn som oppfylte QC-kriteriene

2. juli 2018

Sist bekreftet

1. oktober 2016

Mer informasjon

Begreper knyttet til denne studien

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

JA

IPD-planbeskrivelse

Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.

Studiedata/dokumenter

  1. Datasettspesifikasjon
    Informasjonsidentifikator: 111751
    Informasjonskommentarer: For additional information about this study please refer to the GSK Clinical Study Register
  2. Skjema for informert samtykke
    Informasjonsidentifikator: 111751
    Informasjonskommentarer: For additional information about this study please refer to the GSK Clinical Study Register
  3. Statistisk analyseplan
    Informasjonsidentifikator: 111751
    Informasjonskommentarer: For additional information about this study please refer to the GSK Clinical Study Register
  4. Annotert saksrapportskjema
    Informasjonsidentifikator: 111751
    Informasjonskommentarer: For additional information about this study please refer to the GSK Clinical Study Register
  5. Klinisk studierapport
    Informasjonsidentifikator: 111751
    Informasjonskommentarer: For additional information about this study please refer to the GSK Clinical Study Register
  6. Datasett for individuell deltaker
    Informasjonsidentifikator: 111751
    Informasjonskommentarer: For additional information about this study please refer to the GSK Clinical Study Register
  7. Studieprotokoll
    Informasjonsidentifikator: 111751
    Informasjonskommentarer: For additional information about this study please refer to the GSK Clinical Study Register

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere